Moderna, Inc. business relationships

“In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).” SEC filing

“Consequently, we announced that we were planning to start a confirmatory vaccine efficacy study, P304, funded by project financing through Blackstone Life Sciences, a collaboration we announced in 2024.” SEC filing

“We are developing mRNA-4157 in collaboration with Merck.” SEC filing

“Contingent upon regulatory approval in the U.S. and only if the approval is dependent on data from the funded activities, Blackstone will be entitled to receive low single-digit percentage royalties and up to $ 750 million in sales milestone payments.” SEC filing

“We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology, such as our collaboration with Immatics N.V. to pioneer novel and transformative therapies for cancer patients with high unmet medical need.” SEC filing

“In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited (together, Vertex).” SEC filing

“...vanced Research Projects Agency (DARPA) and the Gates Foundation and from strategic alliances with Merck & Co., Inc (Merck), Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, Vertex) and others to discover, develop, and commercialize potential mRNA medicines.” SEC filing

“Intismeran autogene is being developed as part of a collaboration with Moderna, Inc.” SEC filing

“She also helped establish strategic partnerships with Moderna and Novavax and supported the collaboration with the Government of Japan to secure COVID-19 vaccine supply during the pandemic.” SEC filing

“Payments by Moderna under the Settlement Agreement will be made directly to Genevant and Arbutus consistent with the terms of a cross-license agreement (as amended, the "Cross-License Agreement") entered between Genevant (as assignee of GSL) and Arbutus.” SEC filing

“Through the Moderna-Vertex collaboration, the mRNA-3692 / VX-522 asset for CF is in Phase I.” SEC filing

“...ing solutions and the data generated by our multi-omic technology platform provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.” SEC filing

“Except for the Moderna Milestone, the Company did not recognize any variable consideration with regards to the development milestones and sales-based milestones with its customers for the year ended December 31, 2025 and 2024, as they are deemed not probable.” SEC filing

“Research, Option and License Agreement with Moderna” SEC filing

“Immatics concluded that the Clinical Combination is not a contract with a customer and should not be accounted for under IFRS 15, due to the fact that Moderna does not act as a customer and Immatics does not act as a vendor with regard to the Clinical Combination.” SEC filing

“Unlike IMA402 and IMA401, this TCER, in-licensed by Moderna, is not administered as protein-based biologic but is encoded in Moderna's proprietary mRNA delivery system enabling in vivo production of the TCER molecule by the patient's own body.” SEC filing

“We achieved a €4.3 million ($5.0 million) milestone from our collaboration partner Moderna in December 2025, related to a contract modification.” SEC filing

“In 2016, we entered into a strategic collaboration and licensing agreement with Moderna, Inc. ("Moderna"), pursuant to” SEC filing

“• Moderna, Inc. In 2016, we entered into a collaboration with Moderna for the identification and development of” SEC filing

“On April 26, 2024 (the "Termination Date"), we and ModernaTx, Inc. ("Moderna") mutually terminated the Strategic Collaboration and License Agreement, dated October 29, 2021 (the "Moderna Agreement"), by and between us and Moderna.” SEC filing

“Pursuant to the terms of the Moderna Agreement, the Company and Moderna collaborated on the research and development of in vivo genome editing therapies directed at certain targets and the commercialization of such genome editing therapies.” SEC filing

“...ccounting for a substantial portion of our revenue and accounts receivable; in particular, we currently derive a substantial portion of our revenue from two of our largest customers, Moderna and the VA MVP, and in the past have derived a substantial portion of our revenue from other large customers.” SEC filing

“...y collaborations to develop companion diagnostic tests, that we have entered (for example, our strategic alliances with Moderna and Merck; and our collaborations with Tempus; Myriad; ClearNote Health, Inc.; Cancer Research UK, University College London, and the Francis Crick Institute (the TRACERx s...” SEC filing

“Other companies with selective KRAS inhibitors include AstraZeneca (in collaboration with Usynova), BioNTech, Roche, Merck/Moderna, Boehringer and Gilead.” SEC filing

“The Company is also eligible to receive tiered royalties from high-single digit to low-teen percentage rates of annual global net sales of any products that are commercialized under the Moderna Agreement.” SEC filing

“Moderna will pay us tiered royalties on global net sales of Moderna Licensed Products from high single digit to low-teen percentages, subject to certain reductions.” SEC filing

“Additionally, we entered into a collaboration with Moderna for the development of mRNA based product candidates.” SEC filing